IMCR
Immunocore Holdings PLC - ADR

499
Loading...
Loading...
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
493

Frequently Asked Questions

What is Market Cap of Immunocore Holdings plc - ADR?
What is the 52-week high for Immunocore Holdings plc - ADR?
What is the 52-week low for Immunocore Holdings plc - ADR?
What is Immunocore Holdings plc - ADR stock price today?
What was Immunocore Holdings plc - ADR stock price yesterday?
What is the PE ratio of Immunocore Holdings plc - ADR?
What is the Price-to-Book ratio of Immunocore Holdings plc - ADR?
What is the 50-day moving average of Immunocore Holdings plc - ADR?
How many employess does Immunocore Holdings plc - ADR has?

Latest IMCR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.